证券代码：300595 证券简称：欧普康视 公告编号：2025-042 欧普康视科技股份有限公司 关于2021年限制性股票激励计划首次授予第三个解除限售 期和预留授予第二个解除限售期解除限售条件未成就 暨拟回购注销部分限制性股票的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、公司 2021 年限制性股票激励计划首次授予第三个解除限售期和预留授 予第二个解除限售期解除限售条件均未成就，本次涉及激励对象共有 42 人，其 中首次授予部分 37 人，预留授予部分 5 人。 2、公司拟回购注销未满足解除限售条件的 42 位激励对象所持有的已获授 但尚未解除限售的限制性股票合计 337,977 股，其中（1）首次授予部分涉及 37 名激励对象合计 264,752 股，首次授予股份回购价格为 30.087 元/股；（2）预留 授予部分涉及 5 名激励对象合计 73,225 股，回购价格为 17.703 元/股。回购股票 占目前公司总股本 896,152,386 股的 0.0377%。 3、本次拟用于回购的资金合计为 9,261,895.60 元，回 ...

Financial Performance - The company's revenue for Q1 2025 was ¥478,212,588.13, representing a 2.95% increase compared to ¥464,528,576.94 in the same period last year[5]. - Net profit attributable to shareholders decreased by 16.93% to ¥160,278,200.05 from ¥192,953,174.53 year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥147,281,543.93, down 11.59% from ¥166,587,271.85 in the previous year[5]. - Basic and diluted earnings per share decreased by 17.21% to ¥0.1789 from ¥0.2161 year-on-year[5]. - Total operating revenue for the current period reached ¥478,212,588.13, an increase of 2.9% compared to ¥464,528,576.94 in the previous period[30]. - Net profit for the current period is 173,700,569.54, a decrease of 17.94% compared to 211,851,985.06 in the previous period[32]. - Operating profit for the current period is 203,433,093.09, down from 242,775,318.18, reflecting a decline of 16.24%[32]. - Total comprehensive income for the current period is 170,907,930.41, down from 216,277,844.28, reflecting a decrease of 21.00%[32]. Cash Flow and Assets - Operating cash flow for the period was ¥198,073,915.56, a slight increase of 0.84% compared to ¥196,421,532.75 in the same quarter last year[5]. - The company's cash and cash equivalents decreased to ¥692,469,148.14 from ¥758,365,298.49, reflecting a decline of 8.7%[26]. - The net cash increase in cash and cash equivalents was -¥67,254,173.11, an improvement of 15.97% compared to -¥80,038,962.62 in the same period last year[15]. - Cash flow from operating activities is 198,073,915.56, slightly up from 196,421,532.75, indicating a growth of 0.33%[35]. - Investment activities resulted in a net cash outflow of -215,539,960.37, an improvement compared to -230,776,069.02 in the previous period[35]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 65,114[17]. - The largest shareholder, Tao Yuequn, holds 33.35% of shares, totaling 298,890,828 shares[17]. - Nanjing Otao Information Technology Co., Ltd. holds 11.60% of shares, totaling 103,974,521 shares, with 75,629,079 shares pledged[17]. - The total number of shares held by the top 10 shareholders is significant, with the largest holding being 298,890,828 shares[17]. - The company has a total of 224,168,121 restricted shares held by Tao Yuequn, which are subject to management lock-up[19]. - The company has 383,352 restricted shares held by Fu Zhiying, with 25,000 shares released during the period[19]. - The top 10 shareholders do not have any reported changes in their financing and securities lending activities[18]. - The total number of shares with unlimited sale conditions held by the top 10 shareholders is 103,974,521 shares[18]. - There is no indication of any related party transactions among the top shareholders[18]. Expenses and Liabilities - Total operating costs amounted to ¥288,782,761.42, up 17.1% from ¥246,507,886.38 in the previous period[30]. - Sales expenses increased to 124,498,697.45 from 109,802,599.13, marking a rise of 13.36%[32]. - Research and development expenses rose to 9,372,616.78 from 8,116,022.14, an increase of 15.51%[32]. - Total liabilities increased to ¥932,115,142.40 from ¥887,237,280.20, representing a growth of 5.1%[28]. Asset Management - Total assets increased by 4.08% to ¥6,277,256,584.56 from ¥6,030,901,444.15 at the end of the previous year[5]. - Accounts receivable increased to ¥293,614,848.91, up 9.7% from ¥267,619,184.85[26]. - The total equity attributable to shareholders increased to ¥4,854,409,452.80 from ¥4,697,006,548.89, reflecting a growth of 3.3%[28]. - The company reported a significant increase in inventory, which rose to ¥161,344,400.57 from ¥158,054,167.28, indicating a growth of 1.4%[27]. Stock Incentive Plans - The company has implemented various stock incentive plans with different effective periods, including 12 months, 24 months, 36 months, 48 months, and 60 months from the date of grant registration[20]. - A total of 116,077 shares are locked for executives, with 25% calculated as transferable shares for the current year[20]. - The stock incentive plan allows for the unlocking of shares within the legal transfer limit for executives[20]. - The company has a total of 125,000 shares for executive Shi Xianmei, with 100,000 shares available for transfer after 60 months[21]. - Executive Dong Guoxin has 125,000 shares, with 100,000 shares available for transfer after 60 months[21]. - Executive Zhu Zhe has 87,975 shares, all available for transfer after 48 months[22]. - Executive Cheng Jing has 100,000 shares, with 80,000 shares available for transfer after 60 months[22]. - Executive Zhang Yibing has 82,500 shares, with 66,000 shares available for transfer after 60 months[22]. - Executive Qi Min has 75,000 shares, with 60,000 shares available for transfer after 24 months[22]. - The company continues to execute its stock incentive plans based on the effective periods established[21].

证券代码：300595 证券简称：欧普康视 公告编号：2025-037 欧普康视科技股份有限公司 关于收到医疗器械变更注册（备案）文件的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 欧普康视科技股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局颁发的《中华人民共和国医疗器械变更注册（备案）文件》（注册证编号： 国械注准 20193160702），公司申请"硬性接触镜护理液"的医疗器械注册证变 更事项已通过审批。现将具体信息公告如下： 一、变更的基本情况 1、注册证编号：国械注准 20193160702； 4、备注：本文件与"国械注准 20193160702"注册证共同使用； 5、审批部门：国家药品监督管理局； 6、批准日期：2025 年 4 月 17 日。 二、对公司的影响及风险提示 上述医疗器械注册证"产品技术要求"的变更，有助于保障该产品的合规与 可持续性，有利于增强公司产品的综合竞争力。上述产品未来具体的生产、销售 情况可能受到市场环境等因素影响，对公司未来经营业绩的影响存在不确定性。 敬请广大投资者注意防范投资风险，谨慎决策。 特此 ...

天禾律师 股东大会法律意见书 安徽天禾律师事务所 关于欧普康视科技股份有限公司 2024 年年度股东大会法律意见书 天律意 2025 第 00914 号 致：欧普康视科技股份有限公司 根据《中华人民共和国公司法》（下称"《公司法》"）、《中华人民共和 国证券法》（下称"《证券法》"）、中国证券监督管理委员会《上市公司股东 大会规则》（下称"《股东大会规则》"）以及《欧普康视科技股份有限公司章 程》（下称"《公司章程》"）的有关规定，安徽天禾律师事务所接受欧普康视 科技股份有限公司（下称"公司"）委托，指派张大林、冉合庆律师（下称"天 禾律师"）出席公司 2024 年年度股东大会（下称"本次股东大会"），并对本 次股东大会相关事项进行见证，出具法律意见。 本法律意见书是天禾律师根据对本次股东大会事实的了解及对我国现行法 律、法规和规范性文件的理解而出具的。 天禾律师同意将本法律意见书作为本次股东大会的法定必备文件予以公告， 并依法对所出具的法律意见书承担责任。 天禾律师根据《证券法》相关规定的要求，按照律师行业公认的业务标准、 道德规范和勤勉尽责精神，对本次股东大会的召集、召开、与会人员资格、表决 程序及其他相 ...

证券代码：300595 证券简称：欧普康视 公告编号：2025- 036 欧普康视科技股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会召开期间无否决提案的情况； 2、本次股东大会未出现涉及变更以往股东大会已通过决议的情况。 一、会议召开和出席情况 1、会议召开时间： 现场会议时间：2025 年 4 月 22 日 14:45 网络投票时间：通过深圳证券交易所交易系统网络投票时间为 4 月 22 日 9:15-9:25，9:30-11:30 和 13:00-15:00；深圳证券交易所互联网投票系统投票 时间为 4 月 22 日 9:15 至 15:00。 2、会议召开地点：合肥市高新技术开发区望江西路 4899 号 2 号楼二楼会议 室。 3、会议召开方式：现场投票与网络投票相结合的方式。 4、会议召集人：公司第四届董事会。 1 （一）出席本次股东大会的股东及股东代理人总计 429 人，代表股份 338,573,149 股，占公司表决权股份总数的 37.7808%。 （1）出席现场会议股东 ...

证券代码：300595 证券简称：欧普康视 公告编号：2025-035 欧普康视科技股份有限公司（以下简称"公司"）于 2024 年 12 月 24 日披 露了《关于持股 5%以上股东减持股份预披露公告》（公告编号：2024-102）， 持有公司股份 122,790,521 股的股东南京欧陶信息科技有限公司（以下简称"南 京欧陶"）计划在本公告披露之日起十五个交易日后的三个月内通过集中竞价交 易或大宗交易方式合计减持不超过公司股份总数 3%。其中，通过集中竞价交易 减持的股份总数不得超过公司总股本的 1%；通过大宗交易方式减持的股份总数 不得超过公司总股本的 2%。 公司于 2025 年 3 月 11 日披露了《关于持股 5%以上股东减持公司股份触及 1%整数倍的公告》（公告编号：2025-010），南京欧陶在 2025 年 3 月 7 日通过 大宗交易的方式合计减持公司股份 896 万股，占公司总股本的 1.00%。本次权益 变动后，南京欧陶的持股比例由 13.70%变动为 12.70%，变动触及 1%的整数倍。 公司于 2025 年 4 月 1 日披露了《关于持股 5%以上股东减持公司股份触及 1% 整数 ...

证券代码：300595 证券简称：欧普康视 公告编号：2025-034 欧普康视科技股份有限公司 关于持股5%以上股东部分股份补充质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 欧普康视科技股份有限公司（以下简称"公司"）于近日收到公司持股 5% 以上股东南京欧陶信息科技有限公司（以下简称"南京欧陶"）通知，获悉其将 持有公司股份 60 万股在山西证券股份有限公司办理了补充质押。现将具体情况 公告如下： 一、股东股份质押的基本情况 | | 是否为控 | | 占其 | 占公 | | 是否 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股股东或 | 本次质押数 | 所持 | 司总 | 是否 | 为补 | 质押 | 质押 | | 质押 | | 名称 | 第一大股 | 量（股） | 股份 | 股本 | 为限 | 充质 | 起始日 | 到期日 | 质权人 | 用途 | | | 东及其一 | | 比例 | 比例 | 售股 | 押 | | ...

Financial Performance - The company's operating revenue increased by 4.40% year-on-year, while net profit attributable to shareholders decreased by 14.16% [1] - In 2024, the company recorded a significant decline in net profit in Q4, attributed to non-operational factors such as goodwill impairment and bad debt provisions [2] - The company made provisions for long-term equity investment impairment, bad debt, and goodwill impairment totaling 67.14 million yuan, a substantial increase year-on-year [4] Business Strategy - The company plans to focus on building its own brand rather than primarily acting as an OEM for its subsidiary, Duozhi Medical, which has a daily production capacity of no less than 80,000 pieces [2] - The company aims to expand its optical service terminals, with a focus on cost control and improving single-store profitability [4] - The average time for optical terminals to reach breakeven is generally within three years, depending on the scale of the operation [7] Product Development - Sales revenue from the main product, orthokeratology lenses, decreased by 6.73% year-on-year due to weak high-end consumption and intensified competition [3] - The company has made breakthroughs in R&D, with new generation orthokeratology lenses and scleral lenses having completed clinical trials and expected to be launched soon [3] - The company is exploring new myopia control products, such as atropine eye drops and defocus lenses, to enhance its market position [3] Sales and Marketing - Sales expenses increased by 22.40% year-on-year, primarily due to personnel increases and promotional activities [6] - The company has strengthened its technical services and product promotion efforts, which helped stabilize market share despite a decline in main product sales [6] Investment and Capital Management - The company is committed to using 75% of the proceeds from a 500 million yuan acquisition of 13 subsidiaries for stock buybacks, with performance-based milestones [5] - The management's compensation is linked to annual performance, with bonuses decreasing in line with performance declines [4] Talent Management - The company has implemented a dual incentive mechanism for core technical personnel, including project-based rewards and a performance-based salary system [6] - The company maintains a low turnover rate among its core personnel, indicating effective talent retention strategies [6]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [2][29]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 5.20% from March 28 to April 10, 2025, which is approximately 0.18 percentage points lower than the index [14][29]. - Most sub-sectors within the industry recorded negative returns during the same period, with blood products and offline pharmacy sectors showing gains of 7.36% and 1.41%, respectively, while medical R&D outsourcing and in vitro diagnostics faced declines of 21.38% and 10.62% [15][29]. - Approximately 17% of stocks in the industry recorded positive returns, while around 83% experienced negative returns during the reporting period [16][19]. - The overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry is approximately 38.81 times, which is 3.38 times relative to the CSI 300, indicating a decline in industry valuation and positioning at a relatively low level compared to recent years [20][29]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, with a decline of 5.20% from March 28 to April 10, 2025 [14]. - Most sub-sectors recorded negative returns, with blood products and offline pharmacies leading in gains [15]. - About 17% of stocks in the industry had positive returns, while 83% had negative returns [16]. 2. Industry News - The national Chinese medicine procurement alliance began centralized procurement and information maintenance for selected drugs starting April 9, 2025, involving 20 product groups and 95 products, with 174 drugs selected [26]. 3. Important Announcements from Listed Companies - Zai Lab received approval for clinical trials of its drug ZG005 for use in combination with chemotherapy for digestive tumors [27]. - Opcon Vision received a medical device registration certificate for its orthokeratology contact lenses [28]. 4. Industry Weekly Perspective - The report suggests focusing on investment opportunities in medical devices and innovative drugs, particularly those with import substitution potential [29]. - Recommended stocks include Mindray Medical, Yuyuan Pharmaceutical, and others across various segments such as medical aesthetics and innovative drugs [30].

Group 1 - The company, Opcon Vision (300595), has received a medical device registration certificate from the National Medical Products Administration for its new product, "Orthokeratology Rigid Gas Permeable Contact Lens" [1] - The product is designed for temporary correction of myopia for users with myopia degrees between -0.50D and -4.00D and astigmatism degrees within 1.50D [1] - The product is non-sterile and requires cleaning and disinfection before use, with a recommended replacement cycle of one year and a shelf life of five years [1]